BBV154, Bharat Biotech’s intranasal vaccine, gets DCGI’s approval for booster dose trials
The trials of Bharat Biotech's intranasal vaccine, BBV154, will take place at nine different sites across the country.
Jan 28, 2022, 15:55 PM ISTBharat Biotech seeks DCGI nod for India's 1st intranasal COVID vaccine
Bharat Biotech submitted a phase 3 clinical trial application to the Drugs Controller General of India.
Dec 20, 2021, 20:03 PM IST